Iqvia price target raised to $256 from $251 at Baird

Baird analyst Eric Coldwell raised the firm’s price target on Iqvia to $256 from $251 and keeps a Neutral rating on the shares. In the firm’s Q2 Contract Research Organization, or CRO, quarterly review and outlook note, the analyst says “fundamentals weakened, tone shifted, confusion reigned supreme since Q2.” However, Baird adds that “September changed the narrative, keeping us on board into earnings.”